losartan has been researched along with Tachycardia in 8 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the acute effects of E-3174, a human active metabolite of the AT1 receptor antagonist, losartan, on hemodynamic functions in dogs with severe heart failure (HF)." | 7.71 | Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. ( Hanada, K; Ikeda, T; Ikemoto, F; Kawai, N; Nakao, M; Nishikibe, M; Ohta, H; Suzuki, J, 2001) |
| " The intravenous pretreatment with the angiotensin AT1 receptor antagonist losartan (5mg/kg) inhibited the pressor response to RS, but did not affect the concomitant RS-evoked tachycardiac response." | 3.80 | Angiotensinergic neurotransmission in the paraventricular nucleus of the hypothalamus modulates the pressor response to acute restraint stress in rats. ( Busnardo, C; Correa, FM; Tavares, RF, 2014) |
| "The aim of this study was to evaluate the acute effects of E-3174, a human active metabolite of the AT1 receptor antagonist, losartan, on hemodynamic functions in dogs with severe heart failure (HF)." | 3.71 | Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. ( Hanada, K; Ikeda, T; Ikemoto, F; Kawai, N; Nakao, M; Nishikibe, M; Ohta, H; Suzuki, J, 2001) |
| " In genetic and renal hypertensive rats, the antihypertensive effect induced after acute dosing of SR 47436 was similar to that observed after losartan and enalapril." | 1.29 | Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models. ( Canals, F; Cazaubon, C; Galindo, G; Lacour, C; Nisato, D; Segondy, D, 1994) |
| "5." | 1.29 | Angiotensin II activates pressor and depressor sites of the pontomedulla that react to glutamate. ( Chai, CY; Chen, SY; Lin, AM; Tseng, CJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busnardo, C | 1 |
| Tavares, RF | 1 |
| Correa, FM | 1 |
| Sá, RW | 1 |
| Haibara, AS | 1 |
| Gomes, PM | 1 |
| Aguiar, GL | 1 |
| Nascimento, RS | 1 |
| Pedrosa, ML | 1 |
| Alzamora, AC | 1 |
| de Oliveira, LB | 1 |
| Cardoso, LM | 1 |
| Gopinathannair, R | 1 |
| Sullivan, RM | 1 |
| Olshansky, B | 1 |
| Stewart, JM | 1 |
| Taneja, I | 1 |
| Glover, J | 1 |
| Medow, MS | 1 |
| Lacour, C | 1 |
| Canals, F | 1 |
| Galindo, G | 1 |
| Cazaubon, C | 1 |
| Segondy, D | 1 |
| Nisato, D | 1 |
| Chai, CY | 1 |
| Chen, SY | 1 |
| Lin, AM | 1 |
| Tseng, CJ | 1 |
| Farah, VM | 1 |
| Moreira, ED | 1 |
| Ushizima, M | 1 |
| Cestari, IA | 1 |
| Irigoyen, MC | 1 |
| Krieger, EM | 1 |
| Suzuki, J | 1 |
| Ohta, H | 1 |
| Hanada, K | 1 |
| Kawai, N | 1 |
| Ikeda, T | 1 |
| Nakao, M | 1 |
| Ikemoto, F | 1 |
| Nishikibe, M | 1 |
1 trial available for losartan and Tachycardia
| Article | Year |
|---|---|
Angiotensin II type 1 receptor blockade corrects cutaneous nitric oxide deficit in postural tachycardia syndrome.
Topics: Administration, Cutaneous; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Blood Flow Ve | 2008 |
7 other studies available for losartan and Tachycardia
| Article | Year |
|---|---|
Angiotensinergic neurotransmission in the paraventricular nucleus of the hypothalamus modulates the pressor response to acute restraint stress in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pr | 2014 |
Changes in cardiovascular responses to chemoreflex activation of rats recovered from protein restriction are not related to AT
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Bradycardia; Ca | 2017 |
Slower heart rates for healthy hearts: time to redefine tachycardia?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; | 1994 |
Angiotensin II activates pressor and depressor sites of the pontomedulla that react to glutamate.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Bradycardia; C | 1996 |
Acute AT1 receptor blockade does not improve the depressed baroreflex in rats with chronic renal hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Baroreflex; Brad | 2000 |
Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |